Important regulatory notice. No peptide sold as a research-use-only reference compound is licensed by the MHRA as a hormonal-balance medicine in the United Kingdom. This page is a literature-context overview of compound families discussed in published endocrinology research. It is not personal-use guidance. Peptides Lab UK does not endorse any human or veterinary use of any unlicensed peptide. Hormonal questions in any clinical context are a matter for a registered prescriber, typically through NHS endocrinology services.
Quick research summary. The published endocrinology research literature spans the HPG axis (hypothalamic-pituitary-gonadal), HPT axis (thyroid), HPA axis (stress and cortisol) and somatotropic axis (growth hormone). Several peptide and peptide-related compound families appear in this research record across these axes. Many of the compounds in this space appear on the WADA Prohibited List for sport and most are not licensed for human use in the United Kingdom.
Endocrinology biology context
Hormonal biology is structured around several physiological axes, each with its own peptide signalling cascade. The HPG axis involves GnRH, LH and FSH. The somatotropic axis involves GHRH, growth hormone, IGF-1 and the GH-secretagogue family. The HPA axis involves CRH, ACTH and cortisol biology. The HPT axis involves TRH, TSH and thyroid hormones. Steroidogenesis pathways and feedback regulation are tightly characterised in the published literature.
Compound families that appear in the published endocrinology research record
Cell-culture, animal-model and small-clinical research has discussed several peptide families across the endocrine axes. Examples include GHRH analogues, GH-secretagogue peptides (GHRPs and similar), gonadorelin and kisspeptin-related research peptides, melanocortin-pathway peptides, and oxytocin-system peptides. Many of these appear on the WADA Prohibited List under peptide hormones or related categories.
Licensed UK hormonal medicines (separate context)
Many MHRA-licensed prescription medicines exist in UK endocrinology, including levothyroxine for thyroid replacement, hydrocortisone for adrenal insufficiency, growth hormone in defined paediatric and adult indications, gonadotropins in defined fertility indications, and many others. These are accessed through NHS endocrinology pathways and are entirely separate from the research-peptide marketplace.
UK regulatory and sport-testing position
No research-use-only peptide on this site is a licensed treatment for any endocrine condition. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. Several of the peptides discussed in endocrinology research contexts are also banned in sport under the WADA Prohibited List.
For laboratory researchers
Endocrinology researchers may use peptide reference compounds in in-vitro and small-animal model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.
If you have a hormonal concern
The standard NHS pathway is via your GP, who can refer to specialist endocrinology services where appropriate. The Society for Endocrinology (endocrinology.org) is a useful professional resource.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. Several peptides discussed in endocrinology research contexts also appear on the WADA Prohibited List in sport.
